•
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100 million (USD 14.4 million) in a Pre-Series A+ financing round. The round was led by Dr. Jiang Guangce, chairman of DeChuan Investment, with participation from Truking, K2 Venture Partners, and Chang’An Capital, among others. The…
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating RMB 1.45 billion (USD 209.57 million) in revenues, down 63.89% year-on-year (YOY). The significant decline in revenues is attributed to the loss of licensing income and royalties from the COVID-19 antibody etesevimab (JS016/LY-CoV016), which was…
•
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen. The deal grants Chipscreen exclusive development, manufacturing, and commercialization rights to Eucure’s bispecific antibody (BsAb) YH008 in Greater China, including Hong Kong, Macau,…
•
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023 and US giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Tremfya (guselkumab) are on course to obtain breakthrough therapy designations (BTDs). LNP023 is to be awarded BTD status for its use in paroxysmal nocturnal hemoglobinuria…
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has announced a strategic partnership with compatriot firm CorrGene, a rare disease and cancer gene and cell therapy developer headquartered in Wuxi. The collaboration aims to deepen the companies’ involvement in the cell and gene therapy (CGT) field. No…
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater Bay Area special drug entry scheme for its CD38 monoclonal antibody (mAb) Sarclisa (isatuximab). The approval covers Sarclisa in combination with pomalidomide plus dexamethasone for the treatment of multiple myeloma (MM) in patients who have…
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase I clinical study assessing the safety and tolerability of intravitreal injection of IBI333. This recombinant anti-VEGF-A and anti-VEGF-C bispecific antibody (BsAb) was independently developed by Innovent and is being evaluated for the treatment of neovascular…
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving tacit clinical trial approval from the US FDA for its Category 1.1 chemical drug HY3000 nasal spray targeting COVID-19. This approval marks a significant step forward in the development of novel treatments for the virus, offering a new approach to…
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that two randomized, double-blind, placebo-controlled, multi-center Phase III clinical studies for its PCSK9 monoclonal antibody (mAb) ongericimab (JS002) have reached their primary endpoints. The studies focused on primary hypercholesterolemia and mixed hyperlipidemia, demonstrating significant lipid-lowering effects and good safety profiles. Clinical…
•
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a USD 45 million Series B1 investment round. The round was led by premier global industry investors RTW Investments, LP and Qatar Investment Authority, with participation from existing investors, including Qiming Venture Partners and C&D Emerging…
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has accepted for review another market filing for its programmed death-ligand 1 (PD-L1) inhibitor sugemalimab. The filing is for the drug’s use in combination with chemotherapy as a first-line treatment of locally advanced or metastatic gastric/gastroesophageal…
•
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++ financing rounds, raising close to USD 100 million. The funding was led by Guodiao Innovation Private Equity Investment Fund Management (Hainan), Yuexiu Fund, GL Ventures, Zhenji Capital, C&D Emerging Industry Investment, TigerYeah Capital, and others,…
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical Products Administration (NMPA) for its VaxigripTetra, a tetravalent influenza virus split vaccine, for use in children aged 6 to 35 months. This approval is significant as children are a primary susceptible population to influenza, with…
•
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), has been approved by the National Medical Products Administration (NMPA) for the treatment of unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.…
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its Revolade (eltrombopag olamine tablets). The oral thrombopoietin receptor agonist can now be used to treat severe aplastic anemia (SAA) in patients with inadequate previous remission following immunosuppressive therapy. Revolade:…
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its high-end preparation subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, has filed an initial public offering (IPO) with the Hong Kong Stock Exchange. The offering is co-sponsored by Goldman Sachs and CITIC Securities, marking a significant step in the company’s…
•
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the first patient dosing in a Phase I trial for AC0176, an orally bioavailable chimeric degrader molecule targeting the androgen receptor protein. This marks a significant milestone in the development of innovative treatments for prostate cancer.…
•
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor tislelizumab has been approved in China as a first-line therapy for locally advanced unresectable or metastatic gastric/gastroesophageal junction (G/GEJ) tumors where PD-L1 is overexpressed. Specifically, tislelizumab is approved for use in combination with fluorouracil plus…
•
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017, has struck a partnership with Cowell Health, Hillhouse Capital’s healthcare-focused wholly-owned subsidiary. The collaboration aims to enhance the accessibility and affordability of high-quality drugs and services, explore a new full-course management model for cancer patients,…
•
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss pharmaceutical giant Novartis (NYSE: NVS) to deepen commercialization operations surrounding Novartis’s Votrient (pazopanib). Votrient is a first-line targeted treatment for advanced kidney cancer, offering significant benefits to patients in need. Votrient: Next-Generation TKIVotrient, a next-generation…